Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. (April 2016)

• Record Type: Journal Article
• Authors: Koskinas, Konstantinos C.; Zaugg, Serge; Yamaji, Kyohei; García-García, Héctor M.; Taniwaki, Masanori; Klingenberg, Roland; Moschovitis, Aris; Lüscher, Thomas F.; van Tits, Lambertus J.; Matter, Christian M.; Windecker, Stephan; Räber, Lorenz
• Is Part Of: Atherosclerosis. Volume 247(2016)
• Page Start: 154
• Page End: 160
• Publication Date: 2016-04
• Subjects: Atherosclerosis -- Inflammation -- Statin -- Regression -- Myocardial infarction; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2016.02.015
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Objectives: Levels of inflammatory biomarkers associate with changes of coronary atheroma burden in statin-treated patients with stable coronary artery disease. This study sought to determine changes of plaque composition in vivo in relation to high-sensitivity C-reactive protein (hs-CRP) levels in patients with ST-elevation myocardial infarction (STEMI) receiving high-intensity statin therapy. Methods: The IBIS-4 study performed serial (baseline and 13-month), 2-vessel intravascular ultrasound (IVUS) and radiofrequency-IVUS of the non-infarct-related arteries in patients with STEMI treated with high-intensity statin therapy. The present analysis included 44 patients (80 arteries) with serial measurements of hs-CRP. Results: At follow-up, median low-density lipoprotein cholesterol (LDL-C) levels decreased from 126 to 77 mg/dl, HDL-C increased from 44 to 47 mg/dl, and hs-CRP decreased from 1.6 to 0.7 mg/L. Regression of percent atheroma volume (−0.99%, 95% CI −1.84 to −0.14, p = 0.024) was accompanied by reduction of percent fibro-fatty (p = 0.04) and fibrous tissue (p < 0.001), and increase in percent necrotic core (p = 0.006) and dense calcium (p < 0.001). Follow-up levels of hs-CRP, but not LDL-C, correlated with changes in percent necrotic core (p = 0.001) and inversely with percent fibrous tissue volume (p = 0.008). Similarly, baseline-to-follow-up change of hs-CRP correlated with the change in percent necrotic core volume (p = 0.02). Conclusions: In STEMI patients receiving high-intensity statin therapy, stabilization of VH-IVUS–defined necrotic core was confined to patients with lowest on-treatment levels and greatest reduction of hs-CRP. Elevated CRP levels at follow-up may identify progression of high-risk coronary plaque composition despite intensive statin therapy and overall regression of atheroma volume. Highlights: High-intensity statin therapy altered coronary plaque composition following STEMI. Necrotic tissue content increased despite statin treatment and atheroma regression. Changes in necrotic core tissue by VH-IVUS correlated with CRP, but not LDL-C levels. Necrotic core stabilization was confined to patients with greatest reduction of CRP. Future studies should examine possible clinical implications of these findings.